• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 8-K filed by Climb Bio Inc.

    6/5/25 4:05:36 PM ET
    $CLYM
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CLYM alert in real time by email
    8-K
    false 0001768446 0001768446 2025-06-04 2025-06-04
     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

    FORM 8-K

     

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d)

    of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): June 4, 2025

     

     

    CLIMB BIO, INC.

    (Exact Name of Registrant as Specified in its Charter)

     

     

     

    Delaware   001-40708   83-2273741

    (State or Other Jurisdiction

    of Incorporation)

     

    (Commission

    File Number)

     

    (IRS Employer

    Identification No.)

     

    20 William Street, Suite 145

    Wellesley Hills, Massachusetts

      02481
    (Address of Principal Executive Offices)   (Zip Code)

    Registrant’s Telephone Number, Including Area Code: (866) 857-2596

    Not Applicable

    (Former Name or Former Address, if Changed Since Last Report)

     

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

     

    ☐

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ☐

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ☐

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ☐

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class

     

    Trading

    Symbol(s)

     

    Name of each exchange

    on which registered

    Common Stock, par value $0.0001 per share   CLYM  

    The Nasdaq Stock Market LLC

    (The Nasdaq Global Market)

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

    Emerging growth company ☒

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     
     


    Item 5.07

    Submission of Matters to a Vote of Security Holders.

    Climb Bio, Inc. (the “Company”) held its 2025 Annual Meeting of Stockholders on June 4, 2025. The following is a summary of the matters voted on at that meeting.

     

      1.

    The stockholders of the Company elected Judith Dunn, Ph.D., and Stephen Thomas, Ph.D., to the Company’s board of directors, each to serve for a three-year term expiring at the 2028 annual meeting of stockholders and until his or her respective successor has been duly elected and qualified. The results of the stockholders’ vote with respect to such matter were as follows:

     

         Votes For      Votes
    Withheld
         Broker Non-
    Votes
     

    Judith Dunn, Ph.D.

         36,827,909        6,615,228        10,126,633  

    Stephen Thomas, Ph.D.

         41,359,959        2,083,178        10,126,633  

     

      2.

    The stockholders of the Company ratified the selection of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2025. The results of the stockholders’ vote with respect to such matter were as follows:

     

    Votes For

     

    Votes Against

     

    Abstentions

    53,442,396   8,780   118,594


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

          Climb Bio, Inc.
    Date: June 5, 2025     By:  

    /s/ Aoife Brennan

                Aoife Brennan, M.B., Ch.B.
                President and Chief Executive Officer
    Get the next $CLYM alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CLYM

    DatePrice TargetRatingAnalyst
    8/15/2025$9.00Outperform
    Robert W. Baird
    6/6/2025$10.00Outperform
    Oppenheimer
    5/22/2025$7.00Buy
    BTIG Research
    12/2/2024$10.00Outperform
    Leerink Partners
    More analyst ratings

    $CLYM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Robert W. Baird initiated coverage on Climb Bio with a new price target

    Robert W. Baird initiated coverage of Climb Bio with a rating of Outperform and set a new price target of $9.00

    8/15/25 8:18:48 AM ET
    $CLYM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Oppenheimer initiated coverage on Climb Bio with a new price target

    Oppenheimer initiated coverage of Climb Bio with a rating of Outperform and set a new price target of $10.00

    6/6/25 8:35:04 AM ET
    $CLYM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BTIG Research initiated coverage on Climb Bio with a new price target

    BTIG Research initiated coverage of Climb Bio with a rating of Buy and set a new price target of $7.00

    5/22/25 8:24:05 AM ET
    $CLYM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CLYM
    SEC Filings

    View All

    SEC Form 10-Q filed by Climb Bio Inc.

    10-Q - Climb Bio, Inc. (0001768446) (Filer)

    8/12/25 7:15:52 AM ET
    $CLYM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Climb Bio Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Climb Bio, Inc. (0001768446) (Filer)

    8/12/25 7:10:31 AM ET
    $CLYM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 8-K filed by Climb Bio Inc.

    8-K - Climb Bio, Inc. (0001768446) (Filer)

    6/18/25 7:08:36 AM ET
    $CLYM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CLYM
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Climb Bio Reports Second Quarter 2025 Financial Results and Provides Business Updates

    Clinical Trials of Budoprutug in Immune Thrombocytopenia (ITP) and Systemic Lupus Erythematosus (SLE) Underway; Trial of Budoprutug in Primary Membranous Nephropathy (pMN) Expected to Initiate in the Coming Weeks Budoprutug Subcutaneous Formulation Demonstrated High Bioavailability and Favorable Tolerability in Non-clinical Studies; Phase 1 Trial Expected to Initiate in the Coming Weeks, with Initial Data Anticipated in First Half 2026 CLYM116 Focused Webcast Event, Including New Preclinical Data, Planned for September 2025; IND or CTA Submission for IgA Nephropathy (IgAN) Expected in Second Half 2025 Edgar D. Charles, M.D., MSc Appointed Chief Medical Officer Strong Financial Position,

    8/12/25 7:00:00 AM ET
    $CLYM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Climb Bio Appoints Edgar D. Charles, M.D., MSc as Chief Medical Officer

    Dr. Charles, Accomplished Immunology-Focused Drug Developer, Brings More Than 20 years of Biopharma Leadership, Clinical Development, and Operations Expertise Company Also Hires Cindy J. Driscoll, MBA, Financial Executive with Over Two Decades of Experience Guiding Biotechnology Companies, as Senior Vice President, Finance WELLESLEY HILLS, Mass., June 18, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (NASDAQ:CLYM), a clinical stage biotechnology company developing therapeutics for patients with immune-mediated diseases, today announced the appointments of Edgar D. Charles, M.D., MSc as its Chief Medical Officer (CMO) and Cindy J. Driscoll, MBA as Senior Vice President, Finance. "The expansi

    6/18/25 7:00:00 AM ET
    $CLYM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Climb Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

    WELLESLEY HILLS, Mass., May 19, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (NASDAQ:CLYM), a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases, today announced that the Company has granted an inducement equity award to a new employee, pursuant to the Company's 2025 Inducement Plan, as an inducement material to the new employee entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4). The inducement equity award was granted to one new employee on May 19, 2025, and consisted of a non-statutory stock option to purchase up to an aggregate of 120,000 shares of common stock of the Company. The option has an ex

    5/19/25 4:34:52 PM ET
    $CLYM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CLYM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Thomas Stephen Basil was granted 100,375 shares, increasing direct ownership by 49% to 304,657 units (SEC Form 4)

    4 - Climb Bio, Inc. (0001768446) (Issuer)

    8/11/25 4:15:08 PM ET
    $CLYM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President and CEO Brennan Aoife converted options into 68,750 shares and sold $25,154 worth of shares (20,618 units at $1.22) (SEC Form 4)

    4 - Climb Bio, Inc. (0001768446) (Issuer)

    7/1/25 4:37:17 PM ET
    $CLYM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Thomas Stephen Basil converted options into 25,094 shares, increasing direct ownership by 14% to 204,282 units (SEC Form 4)

    4 - Climb Bio, Inc. (0001768446) (Issuer)

    7/1/25 4:32:24 PM ET
    $CLYM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CLYM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Climb Bio Inc.

    SC 13G/A - Climb Bio, Inc. (0001768446) (Subject)

    11/14/24 9:29:34 AM ET
    $CLYM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CLYM
    Leadership Updates

    Live Leadership Updates

    View All

    Climb Bio Appoints Edgar D. Charles, M.D., MSc as Chief Medical Officer

    Dr. Charles, Accomplished Immunology-Focused Drug Developer, Brings More Than 20 years of Biopharma Leadership, Clinical Development, and Operations Expertise Company Also Hires Cindy J. Driscoll, MBA, Financial Executive with Over Two Decades of Experience Guiding Biotechnology Companies, as Senior Vice President, Finance WELLESLEY HILLS, Mass., June 18, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (NASDAQ:CLYM), a clinical stage biotechnology company developing therapeutics for patients with immune-mediated diseases, today announced the appointments of Edgar D. Charles, M.D., MSc as its Chief Medical Officer (CMO) and Cindy J. Driscoll, MBA as Senior Vice President, Finance. "The expansi

    6/18/25 7:00:00 AM ET
    $CLYM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Climb Bio Appoints Seasoned Biotech Leaders to Board of Directors

    WELLESLEY HILLS, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (NASDAQ:CLYM) today announced the appointments of biotech industry veterans Kim Cobleigh Drapkin, CPA, and Bo Cumbo to its Board of Directors. Ms. Drapkin will assume the role of Audit Committee Chair, and Mr. Cumbo will assume the role of Compensation Committee Chair. "We are delighted to welcome Kim and Bo to our Board of Directors at Climb Bio," said Aoife Brennan, President and CEO of Climb Bio. "Kim and Bo each bring three decades of leadership experience in the biotechnology and pharmaceutical industry, offering invaluable perspective as we continue to build the company and advance our pipeline. Their insight

    4/1/25 7:00:00 AM ET
    $ABOS
    $CLYM
    $LENZ
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Climb Bio Appoints Perrin Wilson, Ph.D., as Chief Business Officer

    WELLESLEY HILLS, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (NASDAQ:CLYM) announced today the appointment of Perrin Wilson, Ph.D. as Chief Business Officer. Dr. Wilson is an accomplished leader, with over 17 years of experience in the pharmaceutical and biotech industry. "I am delighted to welcome Dr. Perrin Wilson to the Climb Bio management team," said Aoife Brennan, President and CEO of Climb Bio. "Perrin brings extensive experience and a track record of success across large pharma and biotech to Climb Bio. As Chief Business Officer, she will lead the Company's pre-commercial planning, communications, and business development efforts. Perrin's proven expertise in negotiat

    2/24/25 7:00:00 AM ET
    $CLYM
    Biotechnology: Pharmaceutical Preparations
    Health Care